IGF2BP3 Antibody (YA3490)
(Synonyms: KOC; CT98; IMP3; KOC1; IMP-3; VICKZ3)IGF2BP3 Antibody (YA3490) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IGF2BP3.
-
Host:
Mouse
-
Isotype:
IgG1
-
Application:
WB, IHC-P, FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
IGF2BP3 Antibody (YA3490) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IGF2BP3.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 70-90 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 64 kDa
Purified recombinant fragment of human IGF2BP3 (AA: 430-579) expressed in E. Coli.
affinity purified.
Non-conjugated
Unmodified
IgG1
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
IGF2BP3 is a RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and increases their stability. Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD. Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs[1].
-
Subcellular Localization
Nucleus; Cytoplasm; Cytoplasm, P-body; Cytoplasm, Stress granule
-
Expression
Tissue_specificity:It is expressed (protein level) in fetal liver, fetal lung, fetal kidney, fetal thymus, fetal placenta, fetal ovarian follicles and testicular germ cells, developing oocytes, spermatogonia, and semen. It is also expressed (protein level) in cervical adenocarcinoma, testicular cancer, pancreatic cancer, and renal cell carcinoma. It is widely expressed during fetal development at 8 and 14 weeks of gestation. It is also expressed in ovarian, testicular, brain, placenta, pancreatic cancer tissue, and pancreatic cancer cell lines. -
Isoforms & Post-Translational Modification
O00425 has 2 isomers: O00425-1: 63705 Da (predicted); O00425-2: 21630 Da (predicted).
-
Subunit
Can form homooligomers and heterooligomers with IGF2BP1 and IGF2BP3 in an RNA-dependent manner (PubMed:23640942). Interacts with IGF2BP1 (PubMed:17289661). Interacts with ELAVL1, DHX9, HNRNPU, MATR3 and PABPC1 (PubMed:23640942, PubMed:29476152)
-
SwissProt ID
-
Synonyms
KOC; CT98; IMP3; KOC1; IMP-3; VICKZ3
Documentation
Powered by Bioz
